Literature DB >> 15114608

Clinical spectrum of myelophthisis in cancer patients.

Stephen N Makoni1, Damian A Laber.   

Abstract

Myelophthisis is a form of bone marrow failure due to replacement of hematopoietic tissue by abnormal tissue, most commonly metastatic carcinomas. This results in extramedullary hematopoiesis, typically in the spleen leading to premature release of hematopoietic cells into the circulation. Peripheral blood findings may include nucleated red blood cells, tear drop forms, giant platelets, and immature leukocytes. This is called a leukoerythroblastic picture. The first case demonstrates acute myelophthisis as a presentation of pancreatic cancer. The second case is of extramedullary hematopoiesis as a manifestation of widely metastatic melanoma. The presence of a leukoerythroblastic peripheral blood picture should serve as a valuable clue about a possible underlying malignancy. This late presentation of advanced cancer may now be rarely seen because of early diagnosis and more effective therapies. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15114608     DOI: 10.1002/ajh.20046

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Signet ring cell carcinoma of the rectum: atypical metastatic presentation.

Authors:  Mariana Morales-Cruz; Noel Salgado-Nesme; Alicia Maybi Trolle-Silva; Jorge Humberto Rodríguez-Quintero
Journal:  BMJ Case Rep       Date:  2019-04-30

2.  Myelophthisis as first manifestation of failure of chemotherapy in breast cancer.

Authors:  Leonardo Rodrigues de Oliveira; Thaís Camargos Ferreira; Antônio Carlos Oliveira de Meneses
Journal:  Rev Bras Hematol Hemoter       Date:  2012

3.  The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19 cases.

Authors:  Fahir Ozkalemkas; Ridvan Ali; Vildan Ozkocaman; Tulay Ozcelik; Ulku Ozan; Hulya Ozturk; Ender Kurt; Turkkan Evrensel; Omer Yerci; Ahmet Tunali
Journal:  BMC Cancer       Date:  2005-11-01       Impact factor: 4.430

4.  Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone.

Authors:  Samuel Rosner; Filiz Sen; Michael Postow
Journal:  J Immunother Cancer       Date:  2017-04-18       Impact factor: 13.751

5.  Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review.

Authors:  Youting Bao; Zhichao Liu; Meiying Guo; Butuo Li; Xindong Sun; Linlin Wang
Journal:  Cancer Manag Res       Date:  2018-06-08       Impact factor: 3.989

Review 6.  Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow.

Authors:  Antonio G Solimando; Carmen Palumbo; Mary Victoria Pragnell; Max Bittrich; Antonella Argentiero; Markus Krebs
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

7.  The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.

Authors:  Berna C Özdemir; Janine Hensel; Chiara Secondini; Antoinette Wetterwald; Ruth Schwaninger; Achim Fleischmann; Wolfgang Raffelsberger; Olivier Poch; Mauro Delorenzi; Ramzi Temanni; Ian G Mills; Gabri van der Pluijm; George N Thalmann; Marco G Cecchini
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

8.  Time-dependent interactions of blood platelets and cancer cells, accompanied by extramedullary hematopoiesis, lead to increased platelet activation and reactivity in a mouse orthotopic model of breast cancer - implications for pulmonary and liver metastasis.

Authors:  Hassan Kassassir; Kamil Karolczak; Karolina M Siewiera; Dagmara W Wojkowska; Marcin Braun; Cezary W Watala
Journal:  Aging (Albany NY)       Date:  2020-03-19       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.